Influence of the drug transporters ABCB1 and ABCG2 and enzyme CYP3A4 on survival outcome and pharmacokinetics in patients with non-small cell lung cancer treated with osimertinib
Recruiting
- Conditions
- SCLC
- Registration Number
- NL-OMON25881
- Lead Sponsor
- Erasmus MC dept. of Medical Oncology and dept. of Pulmonology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
Patients who are or have been treated with osimertinib for non-small cell lung cancer (NSCLC) and of
whom blood has been withdrawn for study or diagnostic purposes are eligible for usage in this study.
Exclusion Criteria
No blood available for analysis
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method